Welspun Enterprises Limited has reconstituted its Disclosure Committee in accordance with regulatory requirements under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company announced this development through an official communication to stock exchanges on February 04, 2026.

Regulatory Compliance and Board Approval

The Board of Directors approved the reconstitution during their meeting held on February 04, 2026. This action aligns with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, which mandates companies to maintain proper disclosure mechanisms for unpublished price sensitive information.

The reconstituted committee operates under the company's Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, with the primary responsibility of determining the materiality of events or information that may impact the company's stock price.

Committee Composition

The Disclosure Committee, effective from February 04, 2026, comprises the following positions:

Disclosure and Transparency

The company has made this information publicly available on its official website at www.welspunenterprises.com , ensuring transparency and accessibility for stakeholders. The communication was formally submitted to both BSE Limited and National Stock Exchange of India Limited, where the company's shares are listed under scrip code 532553 and symbol WELENT respectively.

This reconstitution represents part of Welspun Enterprises' ongoing commitment to maintaining robust corporate governance standards and regulatory compliance in its disclosure practices.

Welspun Enterprises Limited has submitted its statement of deviation or variation for the quarter ended December 31, 2025, confirming no deviation in the utilization of proceeds from its convertible warrants issued through preferential allotment. The statement, filed under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was reviewed by the Audit Committee and Board of Directors at their respective meetings held on February 04, 2026.

Issue Details and Fund Raising

The company raised funds through convertible warrants with a total issue size of Rs 1,000.00 crore via preferential issue on October 15, 2025. During the quarter ended December 31, 2025, the company received Rs 250.00 crore, representing 25% of the issue size as subscription amount. The remaining 75% amounting to Rs 750.00 crore will be received upon exercise of conversion option by warrant holders within 18 months from the allotment date of December 01, 2025.

Fund Utilization and Allocation

The deviation statement confirms no utilization of issue proceeds during the quarter ended December 31, 2025. The funds are allocated for two primary objectives: Rs 750.00 crore for infusion into construction of a 6-lane partially elevated highway corridor from Pune to Shirur (NH-753F) in Maharashtra under DFBOT (Toll) mode with a 29-year concession period, and Rs 250.00 crore for general corporate purposes.

Regulatory Compliance and Monitoring

CRISIL Ratings Limited serves as the monitoring agency for the convertible warrants issue. The deviation statement indicates no deviation or variation in the use of funds raised, with no changes in terms of contract or objects requiring shareholder approval. Both the Audit Committee and auditors provided no adverse comments on the fund utilization during the quarter.

Corporate Governance and Disclosure

The statement was signed by Nidhi Tanna, Company Secretary (ACS-30465), and submitted to BSE Limited and National Stock Exchange of India Limited on February 04, 2026. The company maintains transparency by hosting all relevant information on its website at www.welspunenterprises.com . The filing ensures compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding quarterly reporting requirements for fund utilization.